HER2-specific monoclonal antibodies (mAbs) demonstrated favorable clinical outcomes in HER2-positive breast cancer (IHC score 3+ or IHC2+ with gene amplification positive on an in situ hybridization (ISH)). This evidence concerns the gene ERBB2 and breast carcinoma.